MCDERMOTT ADVISES ABOLERIS PHARMA ON ITS SERIES A FINANCING ROUND
September 20, 2023
September 20, 2023
CHICAGO, Illinois, Sept. 20 -- McDermott Will and Emery, a law firm, issued the following news release:
McDermott Will & Emery advised AbolerIS Pharma (AbolerIS), a biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, on its Series A financing.
The round was led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital, with participation from SFPI-FPIM, . . .
McDermott Will & Emery advised AbolerIS Pharma (AbolerIS), a biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, on its Series A financing.
The round was led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital, with participation from SFPI-FPIM, . . .